Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12604119 | 1.00 | PDE2A (0.36) | PDE2ANLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL1987320 | 0.91 | NLRP3 (0.39) | PDE2ANLRP3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL12604721 | 0.90 | PDE2A (0.39) | PDE2AKCNQ3KCNQ2 | |
| SCHEMBL12563381 | 0.88 | PDE2A (0.41) | PDE2ANLRP3 | |
| SCHEMBL12603593 | 0.87 | PDE2A (0.39) | PDE2AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL12697437 | 0.87 | PDE2A (0.38) | PDE2A | |
| SCHEMBL1986283 | 0.87 | PDE2A (0.39) | PDE2AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL1986370 | 0.85 | KCNQ3 (0.37) | PDE2AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL12697429 | 0.85 | KCNQ3 (0.37) | PDE2AKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL12603590 | 0.85 | KCNQ3 (0.41) | KCNQ3KCNQ2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | PDE2A 1939/4885NLRP3 403/4885KCNQ3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.